Single-agent gemcitabine in patients with resistant small-cell lung cancer.
Single-agent gemcitabine in patients with resistant small-cell lung cancer.
复制标题
单药吉西他滨治疗耐药小细胞肺癌患者。
DOI：
10.1023/a:1011104509759
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
Fmnh Schramel
中科院分区：
文献类型：
--
作者：
I. van der Lee;E. Smit;J. van Putten;H. Groen;N. Schlösser;P. Postmus;Fmnh Schramel
客观化
本研究旨在评价吉西他滨对耐药小细胞肺癌(SCLC)患者的疗效和毒性。患者和方法：41例局限性或广泛期小细胞肺癌患者，以前至少接受过一种化疗方案，在结束最后一种方案期间或在最后一种方案结束后三个月内进展，在四周周期的第1、8和15天给予1000 mg/m2吉西他滨治疗。
结果
38名患者的反应是可评估的。总有效率为13%(95%可信区间：6%~27%)。进展时间从4周到20周不等，中位数为8周。中位生存期17周(4~84周)。血液学毒性主要包括NCI-CTC 3级血小板减少(29%)和次要程度的3级白细胞减少(18%)。非血液学毒性轻微，恶心是最常见的报道事件。
结论
吉西他滨在耐药小细胞肺癌患者中有适度的活性。对大多数药物对小细胞肺癌有一定的非交叉耐药性。
OBJECTIVE
This study was conducted to assess the activity and toxicity ofgemcitabine in patients with resistant small-cell lung cancer (SCLC). PATIENTS TAND METHODS: Forty-one patients with limited- or extensive-stage SCLC, who were previously treated with at least one chemotherapeutic regimen and progressed during or within three months of finishing the last regimen, were treated with 1000 mg/m2 gemcitabine on days 1, 8, and 15 of a four-week cycle.
RESULTS
Thirty-eight patients were evaluable for response. Five partial and no complete responses were seen, for an overall response rate of 13% (95% confidence interval (CI): 6%-27%). Time to progression varied from 4 to 20 weeks, with a median of 8 weeks. Median survival was 17 weeks (range 4-84 weeks). Hematological toxicity mainly consisted of NCI-CTC grade 3 thrombocytopenia (29% of patients) and, to a lesser extent, grade 3 leukopenia (18% of patients). Non-hematological toxicity was mild, with nausea being the most commonly reported event.
CONCLUSIONS
Gemcitabine has modest activity in patients with resistant SCLC. There is some non-cross resistance to most agents against SCLC.